Immix Biopharma Announces Comprehensive Cancer Center As Lead Site For NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma 宣佈綜合癌症中心作爲 NXC-201 AL 澱粉樣變臨床試驗的牽頭機構
Immix Biopharma Announces Comprehensive Cancer Center As Lead Site For NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma 宣佈綜合癌症中心作爲 NXC-201 AL 澱粉樣變臨床試驗的牽頭機構
使用瀏覽器的分享功能,分享給你的好友吧